Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC)

References

• The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
   PubMed Web of Science ®Google Scholar
• Raz DJ, Zell JA, Ou S-HI, et al. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193–199.
   PubMed Web of Science ®Google Scholar
• Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118–2127.
   PubMed Web of Science ®Google Scholar
• Dosoretz DE, Katin MJ, Blitzer PH, et al. Medically inoperable lung carcinoma: the role of radiation therapy. Semin Radiat Oncol. 1996;6:98–104.
   PubMed Web of Science ®Google Scholar
• Kaskowitz L, Graham MV, Emami B, et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993;27:517–523.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070.
   PubMed Web of Science ®Google Scholar
• Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:660–665.
   PubMed Web of Science ®Google Scholar
• Sura S, Yorke E, Jackson A, et al. High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer. Cancer J. 2007;13:238–242.
   PubMed Web of Science ®Google Scholar
• Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135.
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys.1991;21:137–146.
   PubMed Web of Science ®Google Scholar
• Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002;54:329–339.
   PubMed Web of Science ®Google Scholar
• Spratt DE, Wu AJ, Adeseye V, et al. Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non-small-cell lung cancer: implications for surveillance. Clin Lung Cancer. 2016;17:177–183.
   PubMed Web of Science ®Google Scholar
• Cuaron JJ, Yorke ED, Foster A, et al. Stereotactic body radiation therapy for primary lung cancers >3 centimeters. J Thorac Oncol. 2013;8:1396–1401.
   PubMed Web of Science ®Google Scholar
• Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharmaceut Statist. 2011;10:150–161.
   PubMed Web of Science ®Google Scholar
• Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer. 2010;68:72–77.
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677–682.
   PubMed Web of Science ®Google Scholar
• Marwaha G, Stephans KL, Woody NM, et al. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size. J Thorac Oncol. 2014;9:1693–1697.
   PubMed Web of Science ®Google Scholar
• Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–1358.
   PubMed Web of Science ®Google Scholar
• Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–S100.
   PubMed Web of Science ®Google Scholar
• Jeppesen SS, Schytte T, Jensen HR, et al. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates. Acta Oncol. 2013;52:1552–1558.
   PubMed Web of Science ®Google Scholar
• Nyman J, Hallqvist A, Lund JÅ, et al. SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121:1–8.
   PubMed Web of Science ®Google Scholar
• Koshy M, Malik R, Mahmood U, et al. Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I non-small cell lung cancer. Radiother Oncol. 2015;114:148–154.
   PubMed Web of Science ®Google Scholar
• Woody NM, Stephans KL, Andrews M, et al. A histologic basis for the efficacy of SBRT to the lung. J Thorac Oncol. 2017;12:510–519.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Nakayama Y, Kitamoto Y, et al. Effect of histologic type on recurrence pattern in radiation therapy for medically inoperable patients with stage I non-small-cell lung cancer. Lung. 2006;184:347–353.
   PubMed Web of Science ®Google Scholar
• Hörner-Rieber J, Bernhardt D, Dern J, et al. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. Radiother Oncol. 2017;125:317–324.
   PubMed Web of Science ®Google Scholar
• Trans-Tasman Radiation Oncology Group (TROG). Hypofractionated radiotherapy (stereotactic) versus conventional radiotherapy for inoperable early stage I non-small cell lung cancer (NSCLC): NCT01014130. Bethesda (MD): National Library of Medicine (US); 2009. [cited 2017 May 17] Available from: http://clinicaltrials.gov/show/NCT01014130.
   Google Scholar
• Ontario Clinical Oncology Group (OCOG). Stereotactic body radiotherapy versus conventional radiotherapy in medically-inoperable non-small lung cancer patients (LUSTRE): NCT01968941. Bethesda (MD): National Library of Medicine (US); 2014. [cited 2017 May 17] Available from: https://clinicaltrials.gov/show/NCT01968941.
   Google Scholar
• Swaminath A, Wierzbicki M, Parpia S, et al. Canadian phase III randomized trial of stereotactic body radiotherapy versus conventionally hypofractionated radiotherapy for stage I, medically inoperable non-small-cell lung cancer – rationale and protocol design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE trial. Clin Lung Cancer. 2017;18:250–254.
   PubMed Web of Science ®Google Scholar